Blue Lake reports positive data from Phase I RSV vaccine trial

Blue Lake Biotechnology has reported positive interim findings from a Phase I clinical trial of its intranasal vaccine candidate, BLB201, to prevent severe respiratory syncytial virus (RSV)-linked disease.